BIOSCRIP

BIOSCRIP PRICES UNDERWRITTEN OFFERING

DENVER, CO, June 16, 2016 - BioScrip,

Inc. (NASDAQ: BIOS) (the "Company" or "BioScrip") today announced the pricing of an underwritten offering

of 40,000,000 shares of its common stock (the "Offering") at a price to the public of $2.00 per share (the "Offering

Price"). Jefferies LLC is acting as the lead joint book-running manager and SunTrust Robinson Humphrey, Inc. is acting as

a passive book-running manager. Craig-Hallum Capital Group LLC is acting as a co-manager. The Company has granted the underwriters

an option for a period of 30 days to purchase up to an additional 5,200,000 shares of the Company's common stock at the Offering

Price. The Company expects to receive approximately $73.38 million in net proceeds from the offering after deducting underwriting

discounts and commissions and other offering expenses payable by the Company, assuming no exercise by the underwriters of their

option to purchase additional shares, or approximately $83.15 million if the underwriters exercise their option to purchase additional

The Offering is being made pursuant to

a registration statement previously filed and declared effective by the Securities and Exchange Commission (the "SEC").

A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are

available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating

to this offering, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520

Madison Avenue, 12th Floor, New York, New York, 10022, Telephone: 877-547-6340, Email: Prospectus_Department@Jefferies.com.

This press release does not constitute

an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities

in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification

under the securities laws of any such state or jurisdiction.

About BioScrip, Inc.

BioScrip, Inc. is a leading national provider

of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities,

healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with

a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site

setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective

care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality

of life for those it serves.

Forward-Looking Statements - Safe Harbor

release includes statements that may constitute "forward-looking statements," that involve substantial risks and uncertainties.

These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can

identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, forward-looking

statements can be identified by words such as "may," "should," "could," "anticipate," "estimate,"

"expect," "project," "intend," "plan," "believe," "predict," "potential,"

"continue" or comparable terms. These forward-looking statements include, among others, statements about the

Company's expectations with respect to the proposed offering, including its intention to offer and sell shares and its intended

use of proceeds from the Offering. Such forward-looking statements involve known and unknown risks, uncertainties and other

factors, which may cause actual results to be materially different from any results expressed or implied by such forward-looking

statements. For example, there are risks associated with market conditions, the underwriters fulfilling its obligations to purchase

the shares in the Offering and the Company's ability to satisfy certain conditions precedent to the closing of the Offering;

as well as the risks described in the prospectus supplement and the Company's periodic filings

with the Securities and Exchange Commission, including, but not limited to, the Company's annual report on Form 10-K for

the year ended December 31, 2015. The Company does not undertake any duty to update these forward-looking statements after

the date hereof, even though the Company's situation may change in the future. All of the forward-looking statements

herein are qualified by these cautionary statements.

For Further Information:

BioScrip Chief Financial Officer

(303) 766-4343 or (303) 518-7100